SIR, In the June issue of this journal, Thonhofer et al. reported on treatment of a patient with Schnitzler syndrome [1] . We would like to comment briefly on their findings.
The observation that the patient deteriorated when started on treatment with tumour necrosis factor (TNF)-inhibitors, adalimumab as well as etanercept, is intriguing, also with regard to pathophysiology. However, the use of TNF-inhibitors in Schnitzler syndrome was already described in 2005 by Lin et al.
[2], whose patient ameliorated when etanercept was given at a dose of 25 mg twice weekly.
Thonhofer et al.
[1] subsequently started the patient on a combination therapy of anakinra, weekly doses of methotrexate and a tapering dose of steroids. The patient responded very well, and anakinra-methotrexate combination therapy was set forth in the key message as treatment of choice. The efficacy of this treatment regimen was also reported by Martinez-Taboada et al.
[3] in 2005. Based on our experience and on data from the literature, the beneficial effect of this combination therapy is most probably solely due to inhibition of interleukin-1 (IL-1) by anakinra. Since our publication of the beneficial effect of monotherapy with anakinra in Schnitzler syndrome [4], we have seen this in at least eight more patients, either in our clinic, published [5, 6] or through personal communication (V. Akhras, London, UK). We feel that co-administration of methotrexate is not indicated, especially in view of its potential side-effects.
We have recently reviewed the cases of Schnitzler syndrome in the literature and concluded that few if any therapies other than the IL-1 receptor antagonist anakinra are able to induce complete remission in Schnitzler syndrome [7] . There is no need for co-administration of methotrexate. From the point of view of efficacy and toxicity, monotherapy with anakinra should be regarded as the treatment of choice in patients with Schnitzler syndrome. We were not aware of the case report published by Lin and Jagannath [3] . These authors mention the effects of 10 weeks treatment with etanercept in a case of Schnitzler's syndrome (SS). This therapy attempt led to a resolution of the fever but initiated an increase of IgM and did not influence the rash. Other symptoms of SS like bone pain, arthralgias or arthritis were not mentioned and treatment with rituximab was initiated subsequently. The judgement by de Koning et al. as amelioration of disease activity caused by anti-tumour necrosis factor (TNF) therapy is thus not unequivocal. Our patient, dissimilar to the case reported by Lin, responded with massive side-effects to adalimumab and etanercept 24 h, and respectively, 72 h after the administration of the TNF blocking agents [2] .
We agree that the use of methotrexate (MTX) in SS is not supported by rational insights into the pathogenesis of this syndrome. Our decision to combine anakinra with MTX was influenced by classical therapy schemata of rheumatoid arthritis. Indeed, we tapered and discontinued MTX in this patient and for the now overseen period of 2 months the patient did not relapse while being treated with anakinra monotherapy.
Disclosure statement: The authors have declared no conflicts of interest.
R. THONHOFER, E. UITZ, W. GRANINGER 1 grounds and was substantiated by the raised cardiac specific muscle enzymes. I, however, think that the cause of recurrent and partially responsive myocarditis in an immunocompromised individual who has a long-standing chronic inflammatory illness, merits further study to exclude other causes for myocarditis. This is especially true when an acclaim for a successful therapeutic regimen is being expressed and its wider use is encouraged.
The negative viridae serology does not exclude viral myocarditis (by far the commonest cause of myocarditis) since tests of many of the viruses implicated in the causation of myocarditis are not part of the routine virology screen. Furthermore, the fact the patient suffers with AOSD does not rule out other specific forms of idiopathic or viral myocarditis [2, 3]. Chronic bacterial, fungal or infiltrative cardiomyopathies are possibilities needing also to be explored [4] .
All these disorders would have similar initial presentation of dilated cardiomyopathy but would greatly differ in the natural course and prognosis of the disease [5, 6] . Many warrant additional or different modalities of therapy and may require cardiac transplant much earlier than cases with inflammatory myocarditis [7] .
The positive response to intravenous immunoglobulin is well reported in various forms of myocarditis, especially with viral myocarditis [8] [9] [10] . Giving anti-tumour necrosis factor (TNF) therapy is yet another reason for being more diligent in excluding cardiac infective process before the inception in this particular case [11] . This patient already had three attacks of acute myocarditis with dramatic course.
For all of the above, I think a histological diagnosis using transvenous cardiac biopsy would be the appropriate step at the outset of any future relapse. The procedure is relatively safe and can be done as a day case [12] . The information gained will be invaluable. Polymerase chain reaction (PCR) for specific viruses and bacterial studies for chronic infective myocarditis can be readily tested [13] . The various histological examinations and immunohistochemical studies will exclude other primary forms and infiltrative disorders. The histopathological picture would after all confirm the diagnosis of inflammatory myocarditis. A biopsy directed therapy would present a solid cause and effect evidence. It would also substantiate the clinical decision to use other targeted therapy.
